INT79247

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.42
First Reported 1998
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 11
Total Number 11
Disease Relevance 1.78
Pain Relevance 7.13

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (Prkcg) plasma membrane (Prkcg) nucleus (Prkcg)
intracellular (Prkcg) response to stress (Prkcg) cytoplasm (Prkcg)
Anatomy Link Frequency
thalamus 2
Prkcg (Rattus norvegicus)
Pain Link Frequency Relevance Heat
Kinase C 34 100.00 Very High Very High Very High
spinothalamic tract 6 99.60 Very High Very High Very High
nMDA receptor 22 98.88 Very High Very High Very High
Thalamus 2 98.68 Very High Very High Very High
nMDA receptor antagonist 6 97.72 Very High Very High Very High
antagonist 17 97.36 Very High Very High Very High
Glutamate 3 97.00 Very High Very High Very High
Calcitonin gene-related peptide 119 96.00 Very High Very High Very High
Hyperalgesia 8 94.88 High High
Neuronal excitability 9 94.52 High High
Disease Link Frequency Relevance Heat
Hyperalgesia 13 94.88 High High
Bordatella Infection 4 94.00 High High
Nociception 12 85.04 High High
Pain 54 81.20 Quite High
Pressure And Volume Under Development 7 77.12 Quite High
Fistula 19 74.48 Quite High
Injury 8 73.72 Quite High
INFLAMMATION 8 73.44 Quite High
Stress 28 61.68 Quite High
Heart Rate Under Development 11 56.00 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In summary, riluzole blocked the persistent sodium current fully, and the calcium one partly, plus it decreased glutamatergic transmission probably via inhibition of PKC that regulated presynaptic NMDA receptors having a facilitatory effect on glutamate release.
Negative_regulation (decreased) of Negative_regulation (inhibition) of PKC associated with glutamate, kinase c and nmda receptor
1) Confidence 0.42 Published 2008 Journal Eur. J. Neurosci. Section Abstract Doc Link 18445055 Disease Relevance 0 Pain Relevance 0.91
Moreover, chelerythrine and GF 109203X diminished the action of phenylephrine at concentration sufficient to inhibit protein kinase C (PKC).
Negative_regulation (diminished) of Negative_regulation (inhibit) of PKC associated with kinase c
2) Confidence 0.42 Published 2001 Journal Auton Neurosci Section Abstract Doc Link 11695703 Disease Relevance 0 Pain Relevance 0.54
In contrast, desensitization of protein kinase C (PKC) or inhibition of tyrosine kinase by herbimycin were ineffective.
Negative_regulation (desensitization) of Negative_regulation (desensitization) of PKC associated with kinase c
3) Confidence 0.41 Published 1998 Journal Neuroendocrinology Section Abstract Doc Link 9873202 Disease Relevance 0.09 Pain Relevance 0.53
The Janus tyrosine kinase inhibitor AG490, the selective protein kinase C (PKC) inhibitor, bisindolylmaleimide 1 (BIM1), as well as rottlerin, a selective blocker of the PKCdelta isoform, but not the cyclooxygenase inhibitor indomethacin, effectively reduced the effect.
Negative_regulation (reduced) of Negative_regulation (inhibitor) of PKC associated with kinase c
4) Confidence 0.41 Published 2005 Journal Brain Section Abstract Doc Link 15817518 Disease Relevance 0.24 Pain Relevance 0.32
In addition, when STT cells were labeled by microinjection of the retrograde tracer, fluorogold (FG), into the thalamus, we found that the proportion of p-NR1-LI STT cells was markedly reduced after PKC inhibition.
Negative_regulation (reduced) of Negative_regulation (inhibition) of PKC in thalamus associated with kinase c, spinothalamic tract and thalamus
5) Confidence 0.36 Published 2004 Journal Brain Res. Section Abstract Doc Link 15312791 Disease Relevance 0 Pain Relevance 1.13
The effect was also attenuated significantly by a PKA inhibitor (H89) or a PKC inhibitor (chelerythrine chloride).
Negative_regulation (inhibitor) of Negative_regulation (inhibitor) of PKC
6) Confidence 0.31 Published 2004 Journal J. Neurophysiol. Section Abstract Doc Link 15486424 Disease Relevance 0.57 Pain Relevance 1.67
M), but not by a PKC inhibitor (GF109203X, 1 ?
Negative_regulation (by) of Negative_regulation (inhibitor) of PKC
7) Confidence 0.26 Published 2010 Journal Mol Pain Section Abstract Doc Link PMC2829526 Disease Relevance 0.28 Pain Relevance 1.32
Moreover, tezosentan prevented the reduction of the cytosolic fraction of PKC?
Negative_regulation (prevented) of Negative_regulation (reduction) of PKC
8) Confidence 0.20 Published 2005 Journal Crit Care Section Body Doc Link PMC1413997 Disease Relevance 0.20 Pain Relevance 0
by specific chemical inhibitors or knockdown of PKC?
Negative_regulation (inhibitors) of Negative_regulation (knockdown) of PKC
9) Confidence 0.18 Published 2010 Journal Journal of Lipid Research Section Abstract Doc Link PMC2903791 Disease Relevance 0.29 Pain Relevance 0.10
In contrast to the results after PKC inhibition, potentiation still occurred after treatment with the protein kinase inhibitor H89 (5 ?
Negative_regulation (results) of Negative_regulation (inhibition) of PKC
10) Confidence 0.11 Published 2007 Journal Mol Pain Section Body Doc Link PMC2206006 Disease Relevance 0 Pain Relevance 0.27
This stimulatory effect is significantly decreased by the elimination of the AP1 site, or blocked by the treatment of the specific extracellular signal-regulated kinase (ERK) inhibitor, or PKC inhibitor.
Negative_regulation (inhibitor) of Negative_regulation (inhibitor) of PKC associated with kinase c
11) Confidence 0.06 Published 2008 Journal Gene Regulation and Systems Biology Section Body Doc Link PMC2733102 Disease Relevance 0.12 Pain Relevance 0.33

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox